Die Xeltis AG (CHE-113.004.605) hat ihren Sitz in Zürich. Der statutarische Zweck der Gesellschaft ist wie folgt definiert: „Die Gesellschaft bezweckt die Forschung, Entdeckung, Entwicklung, Herstellung und Vermarktung von medizinischen, medizinaltechnischen und biomedizinischen Produkten und Dienstleistungen. Die Gesellschaft kann Zweigniederlassungen und Tochtergesellschaften im In- und Ausland errichten und sich an anderen Unternehmen im In- und Ausland beteiligen. Die Gesellschaft kann Grundstücke erwerben, halten und veräussern. Die Gesellschaft kann alle kommerziellen, finanziellen und anderen Tätigkeiten ausüben, welche mit dem Zweck der Gesellschaft im Zusammenhang stehen.“
Team von Wenger Vieli
Das Team von Wenger Vieli wurde von Beat Speck (Partner, M&A) geleitet und umfasste Barbara Brauchli Rohrer (Partner, Tax) und Alessa Waibel (Financial Services).Team von Wenger Vieli
Team von Bond Advocaten
Weiter haben Bond Advocaten bei der Transaktion Xeltis beraten. Das Team bestand aus Joannes de Bont und Florestan van ‚t Hek.
Information von Xeltis über die Finanzierung
Xeltis informiert wie folgt über die Transaktion:
The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will support the acceleration of clinical programmes for three of Xeltis’ revolutionary, restorative devices. The financing is being made available under the European Guarantee Fund (EGF), an EIB Group initiative in partnership with EU Member States to support European companies whose business was impacted negatively by the COVID-19 pandemic.
“In terms of medical technology innovations, what Xeltis is doing almost sounds like science fiction, yet it is already here,” said EIB Vice-President Kris Peeters. “I think Europe can be proud that it is a breeding ground for such cutting-edge technology, which has the potential to significantly impact medical care in a number of fields. I am proud that, with help of the European Guarantee Fund, we can get behind Xeltis to help them accelerate their way out of this difficult global phase.”
Eliane Schutte, Xeltis CEO, added: “EIB financial support can make the difference in the time our restorative heart valves and blood vessels reach patients that today have limited or no options at all for their conditions. Xeltis has the most advanced restorative technology platform in cardiovascular medicine and may positively impact millions of lives.”
Xeltis’ devices are vascular grafts and heart valves designed to turn into living valves and vessels by harnessing the body’s natural healing process and by facilitating tissue formation once implanted. Xeltis’ devices are made of supramolecular polymers shaped — through a process called electrospinning — into a microstructure that allows tissue restoration. Leveraging the versatility of its technology platform, which can be used to improve many types of implants, Xeltis initiated the development of three types of cardiovascular implants: pulmonary heart valves, coronary artery bypass graft and haemodialysis access grafts, the roll-out of which is set to be accelerated by this EIB financing.
